Letter from FDA outlining deficiencies for lead drug causes Axsome stock to crater. Is a CRL on the way?

Letter from FDA outlining deficiencies for lead drug causes Axsome stock to crater. Is a CRL on the way?

Source: 
Endpoints
snippet: 

The FDA has concerns with Axsome’s lead and potential blockbuster drug to treat major depressive disorder, which sent the company’s stock price down by more than 40% early Monday.